PubMed Health⌕ Search

Biomedical subjects

F Bui

Publications and source records attributed to F Bui.

43 records · Page 3Linked to original sources
PubMed1976

TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.

Forty-six patients whose thyroid glands had been ablated for thyroid carcinoma, maintained on replacement treatment with triiodothyronine (T3), have been followed by means of serial determinations of pituitary thyrotropin (TSH) levels and of the TSH response to thyrotropin-releasing hormone (TRH), in order to verify the actual dose required to suppress TSH secretion. The treatment was begun with a dose of T3 roughly related to body weight (about 1 mug/kg/day). The daily dose was sequentially adjusted according to the measured TSH levels. The dose of T3 which reduced serum TSH within the normal limits varied from 40 to 120 mug daily. More precisely, it was as low as 40-50 mug daily in five patients and as high as 90-120 mug daily in three patients. The dose, which was given according to their body weights, varied from 0.75 to 1.12 mug/kg/day. TRH administration produced a marked increase of TSH levels in those patients whose TSH was elevated, and varying responses (from no response to a response three times the normal one) in those patients whose TSH was within the normal limits. In the latter group of patients, an increase of the T3 dosage inhibited the TSH response to TRH. These data suggest that, even though 1 mug/kg/day is an adequate T3 dose for the great majority of patients, the extent of TSH suppression is not surely predictable, but must be evaluated case by case by means of serial determinations of TSH levels and of the TSH response to TRH.

Adenocarcinoma↗
PubMedDate not supplied

Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment.

Measurements of serum triiodothyronine (T3) concentrations were made in 46 patients who had thyroid ablation for thyroid cancer and who were receiving T3 three times a day as suppressive treatment. In all patients thyrotropin (TSH) suppression was confirmed by the inhibition of TSH response to thyrotropin releasing hormone (TRH). The suppressive dose of T3 varied from 40 to 100 micrograms/day (mean +/- SD 72.39 +/- 13.07 micrograms/day). Related to body weight the dose varied from 0.95 to 1.35 micrograms/kg/day (mean +/- SD 1.13 +/- 0.13 micrograms/kg/day). In ten hospitalized patients serum T3 levels were measured at hourly intervals from 08:00 to 23:00. Before the first dose of T3, serum T3 levels were 153 +/- 43 mg/100 ml; after T3 the levels increased promptly reaching after 4 h a peak of 264 +/- 90 ng/100 ml. Afterwards T3 levels showed a similar peak after each dose: 262 +/- 77 and 266 +/- 78 ng/100 ml, slightly decreasing in the intervals between the doses: 227 +/- 63 and 255 +/- 69 ng/100 ml. After the last peak T3 levels showed a slow decline during the night. TSH response to TRH was completely inhibited both at 08:00 and at 16:00. In 36 outpatients T3 levels were measured twice a day and T3 levels were found similar to the ones of the first group. In these patients also TSH response to TRH evaluated at 08:00 was completely inhibited. No important side effect was noted in both groups of patients.

Circadian Rhythm↗
PubMedDate not supplied

Sestamibi scintimammography in pT1 breast cancer: alternative or complementary to X-ray mammography?

The aim of this study was to compare the results obtained using X-ray mammography (MG) and 99mTc-sestamibi scintimammography (SSM) in patients with breast lesions < or = 2 cm. One hundred and thirty-four women (median age 52 years, range 32-78), who had already been selected for open breast biopsy, underwent both MG and SSM prior to surgery. Final pathology showed 27 (20.1%) benign breast lesions and 107 (79.9%) breast cancers (pT1a=5 [4.7%], pT1b=50 [46.7%], pT1c=52 [48.6%]). The sensitivity, positive predictive value, negative predictive value and accuracy were 81.3%, 97.6%, 55.6% and 83.6% for SSM and 83.2%, 89.9%, 48.6% and 79.1% for MG, respectively. The results were similar (p=NS), but patients with breast cancer (BC) undetected by MG were significantly (p<0.05) younger than those in which the tumor was correctly diagnosed, while the age did not affect SSM sensitivity. SSM was more (p<0.05) specific than MG in BC detection both in the overall group of patients (92.6% vs 63.0%) and in those with < or = 10 mm breast lesions (94.7% vs 63.2%). In conclusion, in patients with suspected BC sized < or = 2 cm, SSM may help in surgical planning because of its high specificity, and should be considered complementary to MG, especially in younger women.

Adult↗
PubMedDate not supplied

Noninvasive parathyroid imaging in primary hyperparathyroidism.

Several studies suggested that preoperative localization of abnormal parathyroid (PT) glands may be useful in reducing operative time facilitating parathyroidectomy, especially in patients with ectopic PT glands. At present, noninvasive techniques used to evaluate patients with primary HPT include (1) 99mTc-sestamibi scintigraphy, (2) high-resolution neck ultrasonography, (3) CT scanning, and (4) magnetic resonance imaging (MRI). The sensitivity and positive predictive value of each technique range from 70% to 90%, and a combination of two of more tests may significantly improve the results. In the minimally-invasive era both radioguided and video-assisted parathyroidectomy require an accurate preoperative localization of the abnormal PT glands, and PT imaging should be obtained before surgery in all patients with primary hyperparathyroidism, with the aim of reducing operative time and hospital stay.

Humans↗